Peregrine Pharmaceuticals reported 518K in Interest Expense on Debt for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Agenus AGEN:US $ 13.73M 1.47M
Amgen AMGN:US $ 328M 33M
Biocryst Pharmaceuticals BCRX:US $ 24.02M 0.18M
Bristol Myers Squibb BMY:US $ 313M 13M
Chemocentryx CCXI:US $ 0.59M 0.01M
Eli Lilly And LLY:US $ 81.2M 3.7M
Immunogen IMGN:US $ 1.08M 0.17M
Karyopharm Therapeutics KPTI:US $ 6.31M 371K
Mannkind MNKD:US $ 9.09M 3.97M
Novartis NOVN:VX 202M 1000K
Peregrine Pharmaceuticals PPHM:US 518K 37K
Repligen RGEN:US $ 0.27M 0.02M